| Domain | LDS4-specific finding | Evidence scope | Suggested ontology terms | Key citations |
|---|---|---|---|---|
| Disease identity | Loeys-Dietz syndrome type 4 (LDS4) is a syndromic heritable thoracic aortic disease within the Loeys-Dietz spectrum caused by **TGFB2** pathogenic variants; OMIM **614816** is widely used for LDS4. If a subtype-specific MONDO term is unavailable in the target KB, map cautiously to parent **Loeys-Dietz syndrome** and annotate subtype in free text. | LDS4-specific for gene/subtype; some identifiers from established reference knowledge | MONDO: parent Loeys-Dietz syndrome if subtype unavailable; MeSH: Loeys-Dietz Syndrome | (pqac-00000000, pqac-00000006) |
| Synonyms | TGFB2-related Loeys-Dietz syndrome; TGFB2-related heritable thoracic aortic disease; syndromic thoracic aortic aneurysm due to TGFB2 loss-of-function. | LDS4-specific | — | (pqac-00000000) |
| Causal gene | **TGFB2** (transforming growth factor beta 2) is the established causal gene for LDS4. | LDS4-specific | HGNC: TGFB2 | (pqac-00000000) |
| Inheritance | **Autosomal dominant** inheritance is supported for Loeys-Dietz spectrum disorders and TGFB2-related disease occurs in multigenerational families. | LDS4-specific plus pooled LDS | HPO: Autosomal dominant inheritance | (pqac-00000000, pqac-00000006) |
| Variant mechanism | Founding LDS4 report identified **heterozygous loss-of-function mutations or deletions** in TGFB2 with paradoxical **upregulation of TGF-β signaling in aortic tissue** despite reduced ligand dosage. Reported classes include whole/partial deletions, missense, frameshift, in-frame deletion, and nonsense variants. Germline origin is implied. | LDS4-specific | GO: TGF-beta signaling pathway; extracellular matrix organization | (pqac-00000000, pqac-00000009) |
| Representative pathogenic variants/cohort | Original report described **8 families / 15 patients** with variants including **del**, **p.R330C**, **p.P366H**, **p.R327W**, **p.Y369Cfs*26**, **p.A100_Y104del**, **p.Y99***. | LDS4-specific | Sequence variant classes: deletion, missense, frameshift, in-frame deletion, nonsense | (pqac-00000000, pqac-00000009) |
| Hallmark vascular phenotype | Aortic root aneurysm/dilatation is the major life-threatening feature; supplementary data show aortic root Z-scores roughly **2 to 8.4** and surgical/dissection events including **type B dissection at age 42** and valve-sparing root replacement at root diameters around **45 mm, 48 mm, 56 mm** in some individuals. | LDS4-specific | HPO: Aortic root dilatation; Thoracic aortic aneurysm; Aortic dissection; Arterial tortuosity | (pqac-00000009) |
| Craniofacial phenotype | Frequent craniofacial features include **high-arched palate**, **retrognathia**, **downslanting palpebral fissures**, and occasional **hypertelorism** or **bifid/broad uvula**; craniofacial severity may correlate imperfectly with vascular severity in pooled LDS guidance. | LDS4-specific phenotype table plus pooled LDS interpretation | HPO: High palate; Retrognathia; Downslanted palpebral fissures; Hypertelorism; Bifid uvula | (pqac-00000009, pqac-00000006) |
| Skeletal/connective tissue phenotype | Common systemic findings include **pectus deformity**, **scoliosis**, **arachnodactyly**, **club feet**, **pes planus**, and variable generalized hypermobility. | LDS4-specific | HPO: Pectus excavatum/pectus carinatum; Scoliosis; Arachnodactyly; Talipes equinovarus; Pes planus; Joint hypermobility | (pqac-00000009) |
| Cardiac/non-aortic phenotype | Mitral valve abnormalities (MVP, mitral regurgitation, prior mitral surgery), bicuspid aortic valve in some patients, septal defects, pulmonary artery aneurysm, and supraventricular tachycardia were reported. | LDS4-specific | HPO: Mitral valve prolapse; Mitral regurgitation; Bicuspid aortic valve; Atrial septal defect; Ventricular septal defect; Pulmonary artery aneurysm; Supraventricular tachycardia | (pqac-00000009) |
| Skin/other phenotype | Variable **striae**, **thin/soft skin**, **easy bruising**, **hernia**, keloid or dystrophic scars, livedo reticularis, and occasional **dural ectasia/Tarlov cysts** were reported. | LDS4-specific | HPO: Cutaneous striae; Thin skin; Easy bruising; Hernia; Dural ectasia; Tarlov cyst | (pqac-00000009) |
| Key anatomy involved | Primary: **aortic root**, ascending thoracic aorta, descending thoracic aorta, branch arteries. Secondary: heart valves, craniofacial skeleton, skin, dura. | LDS4-specific with pooled LDS extension | UBERON terms to consider: aortic root, thoracic aorta, mitral valve, palate, skin, dura mater | (pqac-00000009, pqac-00000006) |
| Key cell types/processes | Mechanistic literature for LDS/aortopathy implicates **vascular smooth muscle cells**, fibroblasts/myofibroblasts, and extracellular matrix-producing cells. Core processes include **TGF-β signaling dysregulation**, **SMAD2/3 activation**, and **extracellular matrix remodeling**. | Mostly pooled LDS/aortopathy; not LDS4-exclusive | CL: vascular smooth muscle cell, fibroblast, myofibroblast; GO: TGF-beta receptor signaling pathway, extracellular matrix organization, collagen fibril organization | (pqac-00000000, pqac-00000004) |
| Diagnostic approach | Diagnosis is established by recognizing syndromic HTAD features and confirming a **pathogenic/likely pathogenic TGFB2 variant** via molecular testing. In unclear connective-tissue phenotypes, **multigene HTAD panels**, WES, or WGS are preferred over single-gene testing. | LDS4-specific confirmation; pooled HTAD testing strategy | NCIT/LOINC-style concepts: molecular genetic testing, multigene panel | (pqac-00000003, pqac-00000006) |
| Differential diagnosis | Differentiate from other LDS subtypes (**TGFBR1/2, SMAD2/3, TGFB3**), Marfan syndrome, vascular Ehlers-Danlos syndrome, arterial tortuosity syndrome, and nonsyndromic HTAD. | Pooled LDS/HTAD | — | (pqac-00000003, pqac-00000006) |
| Surveillance | Because LDS can affect the entire arterial tree, expert reviews/guidelines recommend **whole-body vascular imaging from cerebral circulation to pelvis at diagnosis** and repeat imaging based on findings; close monitoring is emphasized, including branch vessels and descending aorta. | Mainly pooled LDS guidance; should be individualized for LDS4 because dissection risk may be lower than TGFBR1/2 but not absent | Imaging concepts: echocardiography, CTA, MRA | (pqac-00000004, pqac-00000006) |
| Medical treatment | Pooled LDS guidance recommends starting **beta-blocker and/or ARB** at diagnosis to reduce aortic growth rate and events; evidence is extrapolated from LDS/Marfan studies rather than LDS4-specific trials. | Pooled LDS evidence | NCIT: Beta-Adrenergic Receptor Blocker; Angiotensin II Receptor Blocker | (pqac-00000004, pqac-00000003) |
| Surgical management | In pooled LDS, surgery thresholds are lower and gene-specific than sporadic aneurysm disease; for **TGFBR1/2** high-risk patients, intervention may be considered at root diameter **≥40 mm**. For **TGFB2**, reviews note **dissection risk is generally not as high as TGFBR1/2/SMAD3**, so thresholds should be individualized rather than automatically applying the most aggressive LDS criteria. | Pooled LDS with specific caution for TGFB2 | NCIT: Aortic root replacement; Valve-sparing aortic root replacement; Bentall procedure | (pqac-00000004, pqac-00000006) |
| Pregnancy/exercise/lifestyle | Direct LDS4 data are sparse. General heritable aortopathy care supports counseling on pregnancy-related aortic risk, blood pressure control, and individualized exercise guidance. Pediatric pooled LDS/MFS data show reduced physical fitness and suggest **tailored exercise programs** may help participation and fatigue, but not as a substitute for vascular precautions. | Mostly pooled evidence | — | (pqac-00000005) |
| Epidemiology | LDS overall is rare; one current trial summary cites estimated prevalence **1/25,000–1/100,000** for LDS, but **LDS4-specific prevalence/incidence are not established**. | Pooled LDS only | — | (pqac-00000001) |
| Prognosis | Prognosis is driven by progression of aortic disease and risk of dissection/rupture. Reviews suggest **TGFB2-associated LDS may have a milder dissection risk than TGFBR1/2**, yet clinically significant aneurysm, distal dissection, and need for surgery still occur. Long-term LDS4-specific survival statistics remain unavailable. | Mixed: LDS4-specific trend plus pooled HTAD prognosis | — | (pqac-00000006, pqac-00000003) |
| Real-world implementation/resources | **GenTAC** enrolled **3706** patients with genetically triggered thoracic aortic disease, including Loeys-Dietz syndrome, with longitudinal clinical data and biospecimens available via NHLBI BioLINCC; useful for natural history and biomarker work. | Pooled registry infrastructure | — | (pqac-00000007) |
| Current trials relevant to LDS | **I-LoDiS / NCT05472519** (completed; n=60) studies immunopathology in LDS and measures TFH cells and intracellular pSMAD2/3. **NCT02504853** is an ongoing NIH natural history/genetics protocol including LDS with food allergy/EoE-related phenotypes. Neither is LDS4-specific. | Pooled LDS | — | (pqac-00000001, pqac-00000008) |
| Major evidence gaps | No robust LDS4-specific prevalence, penetrance, sex ratio, or survival estimates; limited genotype-phenotype correlations beyond the original families; little direct evidence on protective factors, modifiers, gene-environment interactions, omics biomarkers, pregnancy outcomes, pediatric thresholds, or TGFB2-specific drug response. Most management is extrapolated from pooled LDS/HTAD literature. | Evidence-gap statement | — | (pqac-00000003, pqac-00000006) |


*Table: This table summarizes compact, knowledge-base-ready facts for Loeys-Dietz syndrome type 4, distinguishing TGFB2-specific evidence from broader Loeys-Dietz syndrome guidance. It highlights causal genetics, phenotypes, surveillance and treatment practices, trials, and the most important current evidence gaps.*